NWBT- PR from 3/7- Northwest Biotherapeutics Adds UCLA as a Site to Its Pivotal Phase II Brain Cancer Trial
Wednesday March 7, 8:00 am ET
First UCLA Patient Surgery Performed
BOTHELL, Wash., March 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB - News), a biotechnology company focused on cancer immunotherapy, today announced that The University of California at Los Angeles (UCLA) has been added as a clinical site in its ongoing pivotal Phase II trial for DCVax®-Brain for patients with newly diagnosed Glioblastoma multiforme (GBM). The first UCLA surgery was performed by Dr. Linda Liau, M.D., Ph.D., the principal investigator of the clinical trial, and the Director of the Malignant Brain Tumor Program at the UCLA School of Medicine. The UCLA program is one of the leading brain cancer centers in the U.S., treating hundreds of such cases per year. The first UCLA surgery follows recent surgeries in this Phase II trial at Henry Ford Hospital. Nine other clinical trial sites are pending.
.
He who loves money will not be satisfied with money, nor he who loves abundance with its income. This too is vanity.
-Eccl 5:10
